Wright F C, Law C H L, Last L, Khalifa M, Arnaout A, Naseer Z, Klar N, Gallinger S, Smith A J
University of Toronto, Toronto, Ontario, Canada.
Ann Surg Oncol. 2003 Oct;10(8):903-9. doi: 10.1245/aso.2003.01.012.
Adjuvant chemotherapy for patients with stage III (node-positive) colorectal cancer (CRC) reduces mortality by one third. Retrieval of an inadequate number of lymph nodes in the surgical specimen may result in incorrectly designating some patients as stage II (node negative), and consequently, such patients may not be offered appropriate chemotherapy. Recent National Cancer Institute guidelines suggest that a minimum of 12 nodes should be examined to ensure accurate staging.
This population-based study identified stage II (T3N0 and T4N0) CRC cases by using CRC pathology reports (1997-2000) from the Ontario Cancer Registry. Patients aged 19 to 75 years were identified, and demographic, surgical, pathologic, and hospital data were extracted. Factors relating to the number of lymph nodes assessed were examined.
A total of 8848 CRC cases were reviewed, and 1789 stage II cases were identified. Seventy-three percent of cases were designated as node negative on the basis of assessment of <12 lymph nodes. Multivariate analysis showed that age, tumor size, specimen length, use of a pathology template, and academic status of the hospital were significant predictors of the number of lymph nodes assessed.
A subset of patients with CRC in Ontario were assigned stage II disease on the basis of examination of relatively few lymph nodes.
对III期(淋巴结阳性)结直肠癌(CRC)患者进行辅助化疗可使死亡率降低三分之一。手术标本中获取的淋巴结数量不足可能导致将一些患者错误地指定为II期(淋巴结阴性),因此,这些患者可能无法接受适当的化疗。美国国立癌症研究所最近的指南建议,至少应检查12个淋巴结以确保准确分期。
这项基于人群的研究通过使用安大略癌症登记处的CRC病理报告(1997 - 2000年)确定II期(T3N0和T4N0)CRC病例。确定年龄在19至75岁之间的患者,并提取人口统计学、手术、病理和医院数据。检查与评估的淋巴结数量相关的因素。
共审查了8848例CRC病例,确定了1789例II期病例。73%的病例基于对少于12个淋巴结的评估被指定为淋巴结阴性。多变量分析表明,年龄、肿瘤大小、标本长度、病理模板的使用以及医院的学术地位是评估淋巴结数量的重要预测因素。
安大略省一部分CRC患者基于相对较少的淋巴结检查被指定为II期疾病。